The DOI matches its Crossref record.
Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial
Abstract
Purpose: To study the outcome of histologic transformation (HT) in a large prospective cohort of patients with follicular lymphoma (FL) who previously responded to immunochemotherapy. Patients and Methods: After a median 6-year follow-up of 1,018 randomly assigned patients from the PRIMA trial, disease progression was observed in 463 patients, 194 of whom had histologic documentation. Results: Forty patients had histology consistent with HT, and 154 had untransformed FL (median time to recurrence, 9.6 v 22.8 months, respectively; P = .018). Thirty-seven percent of biopsies performed during the first year of follow-up showed HT corresponding to 58% of all HTs. Altered performance status, anemia, high lactate dehydrogenase level, “B” symptoms, histologic grade 3a, and high Follicular Lymphoma International Prognostic Index scores at diagnosis were identified as HT risk factors. Response (complete v partial) to immunochemotherapy or rituximab maintenance had no impact on the risk of HT. After salvage treatment, patients with HT had less frequent complete response (50.3% v 67.4%; P = .03) and more disease progression (28.2% v 9.6%; P < .001) than patients without HT. Estimated overall survival for the patients with HT was poorer (median, 3.8 v 6.4 years; hazard ratio, 3.9; 95% CI, 2.2 to 6.9). Autologous stem cell transplantation improved the outcomes of patients with HT (median overall survival, not reached v 1.7 years) but not of patients with persistent FL histology. Conclusion: HT in patients with FL who previously responded to immunochemotherapy is an early event associated with a poor outcome that may deserve intensive salvage with autologous stem cell transplantation. These data emphasize the necessity for biopsy at the first recurrence of FL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Bachy, E., Seymour, J. F., Feugier, P., Offner, F., López-Guillermo, A., Belada, D., Xerri, L., Catalano, J. V., Brice, P., Lemonnier, F., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01073 · Cited by 290
Self-citationShadman, M., Li, H., Rimsza, L., Leonard, J. P., Kaminski, M. S., Braziel, R. M., Spier, C. M., Gopal, A. K., Maloney, D. G., Cheson, B. D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.5083 · Cited by 86
Metadata
- Authors
- Sarkozy, C., Trneny, M., Xerri, L., Wickham, N., Feugier, P., Leppa, S., Brice, P., Soubeyran, P., Gomes Da Silva, M., Mounier, C., Offner, F., Dupuis, J., Caballero, D., Canioni, D., Paula, M., Delarue, R., Zachee, P., Seymour, J., Salles, G., & Tilly, H.
- Venue
- Journal of Clinical Oncology
- Published
- 2016-08-01
- Volume
- 34
- Issue
- 22
- Pages
- 2575-2582
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2425760010
- Cited by
- 186
- References
- 0
- FWCI
- 18.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial. https://app.cochat.ai/papers/10.1200/jco.2015.65.7163
- The paper
- Sarkozy, C., Trneny, M., Xerri, L., Wickham, N., Feugier, P., Leppa, S., Brice, P., Soubeyran, P., Gomes Da Silva, M., Mounier, C., Offner, F., Dupuis, J., Caballero, D., Canioni, D., Paula, M., Delarue, R., Zachee, P., Seymour, J., Salles, G., & Tilly, H. (2016). Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2015.65.7163
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.